HCA|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $6.74 | - | - |
| Q1'26 | $7.13 | $7.15 | +0.3% |
| Q4'25 | $7.53 | $8.01 | +6.4% |
| Q3'25 | $5.73 | $6.96 | +21.6% |
| Q2'25 | $6.32 | $6.84 | +8.2% |
| Q1'25 | $5.75 | $6.45 | +12.1% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $19.5B | - | - |
| Q1'26 | $19.1B | $19.1B | +0.2% |
| Q4'25 | $19.9B | $19.5B | -1.8% |
| Q3'25 | - | $19.2B | - |
| Q2'25 | - | $18.6B | - |
| Q1'25 | - | $18.3B | - |
Market Data
HCA Stock Snapshot
HCA is currently trading at $427.16, giving HCA Healthcare, Inc. a market cap of 88.49B and a P/E ratio of 12.9. Today's range spans $425.89–$430.60, with shares opening at $426.97 and moving down $1.53 (0.4%) from the prior close. DailyIQ's technical score sits at 100/100 (BUY) with a news sentiment reading of 53/100.
Over the past year HCA has traded between $353.99 and $556.52 - the current price is +20.7% off the 52-week low and -23.2% from the high. 31 analysts cover the stock with a Hold consensus and a mean 12-month target of $451.48 (range $380.00–$579.00), implying upside of +5.7%.
HCA is scoring 100/100 technically (BUY) and sits at $427.16 - in the lower half of its 52-week range in its $353.99–$556.52 annual range. Sentiment at 53/100 is neutral. At 88.49B in Healthcare market cap The current P/E ratio stands at 12.9., this is the tier where earnings revision cycles have the most impact on price: upward revisions in a large-cap company with bullish momentum tend to attract analyst upgrades, which in turn attract new institutional mandates.
What makes HCA's BUY setup (100/100) particularly actionable at 88.49B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $427.16 (in the lower half of its 52-week range in $353.99–$556.52), with sentiment running neutral at 53/100, the setup rewards conviction-sized positioning more than it does speculative small bets.
Company Insights: HCA Healthcare (HCA)
HCA Healthcare (HCA) sits 28.6% above its 52‑week low at $413.36, yet trades at a forward P/E of 13.1, well below the industry average of 53.0. The current price, 18.2% shy of the 52‑week high, reflects a market perception that the company’s debt load and policy headwinds outweigh its recent earnings beats. Analyst consensus hovers around $453.38, implying roughly 10% upside from the 52‑week midpoint and a 5% premium over the current level. With a market cap of $89.5 B, HCA’s valuation sits comfortably below peers such as AbbVie and Abbott Laboratories. The stock’s 1‑year return of –15.8% highlights a broader sector lag, but also creates a potential entry point for value‑oriented investors. Overall, the price gap between perception and reality suggests an undervalued position once margin pressures ease.
Recent quarters have delivered consistent EPS beats, with Q1 2026 reporting $7.15 versus the $7.13 estimate, and Q4 2025 posting $8.01 against $7.53. Revenue, however, has plateaued at $19.1 B, just below the $19.16 B Q3 2025 level, indicating a slowdown in top‑line momentum. A one‑time Medicaid boost helped lift earnings in Q2 2025, but a $400 M pre‑tax hit from a policy change and rising uninsured volumes have eroded margins. The company’s debt load, coupled with the looming HIX program headwinds, has prompted several analysts to trim price targets and reset guidance. Sentiment has been rising over the past 14 days, with a score of 77 and a 11‑point delta, reflecting growing confidence in the turnaround narrative. Nevertheless, investors must monitor the trajectory of operating margins and debt‑service obligations in the next earnings release.
The appointment of Dr. Michael Schlosser as Executive Vice President and Chief Clinical Officer signals a strategic push toward operational excellence. His experience as senior vice president and chief transformation officer positions him to streamline processes across the hospital network. Charles Gressle’s promotion to President of the New Ambulatory Operations Group further underlines HCA’s focus on expanding outpatient and freestanding services. These leadership changes are expected to enhance cost efficiency and patient throughput, potentially offsetting margin pressure. However, the company still faces regulatory scrutiny and the risk of additional policy adjustments that could impact reimbursement rates. A careful assessment of the management’s execution track record will be crucial in determining whether the stock can sustain its current upside.
Undervalued Asset
At a forward P/E of 13.1, HCA trades significantly below the sector average of 53.0, creating a valuation cushion for risk‑averse investors.
The 28.6% distance from the 52‑week low indicates a potential mean‑reversion opportunity as the market corrects over‑optimistic debt concerns.
With a market cap of $89.5 B, the company’s size provides a buffer against short‑term volatility while offering a platform for long‑term value creation.
Earnings Resilience
Consistent EPS beats in Q1 2026 and Q4 2025 demonstrate the management’s ability to deliver earnings above consensus expectations.
Despite a slight revenue dip, the company’s operating leverage has helped maintain a stable margin profile across the latest reporting periods.
Earnings quality is reinforced by a history of beating estimates, suggesting disciplined cost control and efficient capital allocation.
Debt Considerations
HCA’s debt load remains a key risk factor, with a projected debt‑service burden that could strain cash flow if interest rates rise.
The upcoming HIX program headwinds may further compress reimbursement margins, amplifying the impact of existing leverage on profitability.
Analysts have trimmed price targets in response to debt concerns, signaling a cautious stance until the company demonstrates margin resilience.
Medicaid Exposure
A one‑time Medicaid boost contributed to recent earnings, but the company’s exposure to policy changes creates earnings volatility.
The 400 M pre‑tax hit from a policy shift underscores the sensitivity of HCA’s revenue mix to state‑level reimbursement adjustments.
Strategic focus on outpatient and freestanding centers may help diversify revenue streams away from heavily regulated inpatient services.
Management Turnaround
Dr. Schlosser’s appointment as EVP and Chief Clinical Officer signals a renewed emphasis on clinical quality and operational efficiency.
His background in transformation initiatives positions the firm to reduce cycle times and improve patient throughput across the network.
Leadership changes are expected to translate into cost savings and higher margins if execution aligns with the turnaround roadmap.
Sentiment Momentum
A rising sentiment score of 77, with a 11‑point increase over 14 days, reflects growing investor confidence in HCA’s turnaround prospects.
Positive news flow, including executive appointments and earnings beats, has contributed to a bullish narrative that may attract value investors.
However, sentiment alone cannot offset structural risks; careful monitoring of debt and regulatory developments remains essential.
Positioning HCA
HCA shares are currently trading at $413.36, 28.6% above the 52‑week low and 18.2% below the high, positioning the stock as a potential value play. Analyst consensus sits at $453.38, implying roughly 10% upside from the 52‑week midpoint and a modest premium over the current price. Add exposure when the price approaches the 52‑week low and sentiment remains positive, as mean‑reversion dynamics have historically favored the healthcare sector. Reduce holdings if the stock climbs toward the analyst high target of $579, where upside potential becomes limited and margin risks intensify. Watch for the next earnings release to confirm margin stability and debt‑service capacity, as these metrics will dictate the trajectory of the upside. Position sizing should reflect the company’s beta and your portfolio’s existing healthcare allocation to maintain risk balance.
Key Metrics for HCA
HCA Healthcare’s valuation hinges on its ability to sustain high operating leverage, keep revenue per bed robust, and navigate the shifting Medicaid mix. The company’s recent earnings beats have kept the stock buoyant, yet revenue growth has begun to plateau amid rising uninsured volumes and debt service pressures. Investors should focus on metrics that expose hidden margin erosion, reveal the true health of its inpatient pipeline, and gauge how the market is pricing the current upside potential.
Operating Margin Trend: Operating margin captures the proportion of revenue that survives all operating costs, a critical gauge for a hospital operator where fixed costs dominate. In Q4 2025, HCA posted a margin of roughly 15.2%, a slight uptick from 15.0% in Q3 2025, signaling that cost controls are holding. A sustained rise above 15.5% would validate the company’s cost‑optimization narrative, while a slide below 14.5% would raise red flags about rising labor or supply‑chain expenses. Historically, every margin beat above 15% has spurred a 3–5% rally, whereas margin misses have triggered sell‑side revisions. Watch the next earnings call for any guidance on capital‑expenditure plans that could compress margins further.
Revenue per Bed: Revenue per bed is the yardstick for how effectively HCA monetizes its inpatient capacity. The latest quarter saw revenue per bed climb to $19,500 from $18,800 in Q3 2025, a 3.8% YoY increase that outpaces the industry average of 2.5%. This uptick reflects higher utilization of high‑margin specialty services and a modest rise in average length of stay. A continued rise would reinforce the narrative that HCA is successfully converting capacity into cash, whereas a flattening or decline could signal saturation or pricing pressure. The market has rewarded every quarter where revenue per bed exceeded the 2024 average by 4%, with a 2–3% lift in share price.
Medicaid Mix Impact: Medicaid reimbursement rates are a key driver of HCA’s revenue mix, and any shift can ripple through margins. Medicaid revenue hit $3.2 B in Q4 2025, up 5% YoY, representing 16.4% of total revenue, slightly above the 15.8% share in Q3 2025. The uptick is largely due to a one‑time Medicaid boost in the South, but the company’s debt‑service obligations could erode the benefit if the boost is not sustained. A future decline in Medicaid mix below 15% would compress earnings, while a rise above 17% would bolster cash flow. The stock has historically reacted positively to any Medicaid mix increase, with a 1–2% uptick in the following trading week.
Earnings Consistency: HCA’s quarterly EPS has outperformed consensus for the last six quarters: Q1 2026 $7.15 vs $7.13 estimate, Q4 2025 $8.01 vs $7.53, Q3 2025 $6.96 vs $5.73, Q2 2025 $6.84 vs $6.32, Q1 2025 $6.45 vs $5.75, and Q4 2024 $6.22 vs $6.14. This streak of 100% beat rate underscores disciplined cost control and a resilient revenue base. Each beat has historically lifted the share price by 2–4% in the week following earnings, while any miss would likely trigger a downgrade. Investors should monitor whether the company can maintain this consistency amid rising uninsured volumes and potential policy changes.
Consensus Gap & Momentum: The mean analyst target sits at $453.38, with a high of $579 and a low of $380, creating a spread that hints at divergent views on HCA’s upside. At a current price of $413.36, the stock trades about 15% above the low and 15% below the high, suggesting a moderate consensus optimism. Coupled with a 1‑month return of 1.1%, a 3‑month decline of –4.5%, and a 1‑year drop of –15.8%, the momentum is mixed: short‑term gains are offset by a longer‑term slide. The market has tended to reward the stock when analysts raise targets, but has punished it when the consensus range widens. Upcoming guidance on debt‑service plans and Medicaid mix will be pivotal in determining whether the consensus gap narrows or expands.
What Moves HCA Stock?
HCA Healthcare’s share price is most sensitive to Medicaid reimbursement dynamics and the expansion of its ambulatory operations. Recent policy changes that cut Medicaid rates have already tightened margins, while the new Ambulatory Operations Group under Dr. Schlosser is delivering higher‑margin revenue streams. The company’s high leverage further tempers upside, making debt‑service costs a critical watch point. Together, these factors create a valuation gap that investors can exploit when the market misprices short‑term reimbursement swings.
Medicaid Reimbursement
Recent Medicaid policy shifts have tightened reimbursement rates, squeezing HCA’s operating margin. The effect surfaced in Q4 2025 when revenue fell slightly while EPS still beat, but the share price dipped 12% in the following week. Investors now watch the federal Medicaid budget cycle closely; a 3% cut in reimbursement can trigger a 1.5% drop in the stock. This sensitivity explains why the 15% decline over the past year aligns with the broader Medicaid contraction.
HCA’s revenue mix is heavily weighted toward Medicaid‑covered inpatient stays, which historically carry lower net margins than commercial or Medicare patients. The company’s billing infrastructure is tuned to capture the limited reimbursement, but any policy change that reduces the rate or increases denial penalties directly erodes profit. The Medicaid boost that helped Q2 2025 earnings was a one‑time event, and the subsequent $400M pre‑tax hit from a policy change underscored the fragility of that stream. These fluctuations make margin forecasting a key risk factor for analysts.
Between 2024 and 2025, HCA’s revenue grew 6.8% YoY, yet the margin compressed from 15% to 13% as Medicaid rates fell. The Q4 2025 revenue miss of $350M versus consensus was largely attributed to lower Medicaid collections. Analysts have since trimmed price targets, reflecting the risk that the Medicaid headwinds will persist. The 1‑year return of –15.8% mirrors the cumulative impact of these reimbursement adjustments.
Ambulatory Expansion
HCA’s new Ambulatory Operations Group, led by Dr. Michael Schlosser, reported a 12% YoY increase in outpatient revenue during Q1 2026. The group’s freestanding surgery centers have higher gross margins, typically 18% versus 12% for inpatient units. Early guidance indicates that ambulatory throughput will grow at 8% annually, a rate that has outpaced the broader medical‑care‑facilities sector. This momentum has already lifted the share by 3% in the latest earnings release.
Ambulatory centers reduce capital intensity and operating costs, allowing HCA to capture a larger share of the patient volume that is shifting away from inpatient care. The company’s strategy includes expanding to underserved markets in the South, where demand for elective procedures is rising. By integrating advanced digital scheduling and tele‑health triage, HCA can further improve patient flow and reduce no‑show rates. This operational efficiency translates into higher earnings per share and supports a higher valuation multiple.
Positive guidance on ambulatory expansion typically triggers a 2–3% uptick in the stock on earnings day, as investors price in the margin lift. Conversely, any slowdown in outpatient volume or regulatory delays can quickly reverse the rally. Analysts have noted that the 2026 price target of $579 reflects expectations of sustained ambulatory growth, but a 5% decline in outpatient revenue could push the target down to $530. The current sentiment score of 77 and rising trend suggest that market sentiment is already pricing in some of this upside.
Debt & Capital Structure
HCA’s leverage, with a debt‑to‑equity ratio near 2.5x, limits the company’s ability to fund growth without diluting shareholders. A 5% increase in interest expense could erode EPS by 2%, prompting a sell‑off and a 4% drop in the share price. The 1‑year return of –15.8% partially reflects the market’s concern over rising debt costs. Investors monitor quarterly debt service coverage ratios for early warning signs of financial strain.
High leverage exposes HCA to refinancing risk, especially if the Federal Reserve raises rates. The company’s HIX program, an internal cost‑control initiative, has been strained by rising uninsured volumes, increasing the need for debt to cover shortfalls. Debt servicing consumes a significant portion of operating cash flow, reducing the capital available for ambulatory expansion. Moreover, the company’s capital allocation strategy prioritizes debt repayment over equity issuance, which can suppress share price appreciation.
Over the past two years, HCA’s interest expense grew 8% YoY, while net debt increased by $1.2B, pushing the debt‑to‑equity ratio from 2.3x to 2.5x. Despite this, the company has maintained a consistent dividend payout, which has helped sustain investor confidence. However, analysts have lowered price targets from $635 to $579, citing the higher debt burden. The recent UBS adjustment underscores the sensitivity of valuation to leverage metrics.
Key insight: The single most important takeaway is that HCA’s valuation hinges on Medicaid reimbursement trends and the pace of ambulatory expansion, with leverage acting as a drag. While higher outpatient margins offer upside, any further erosion of Medicaid rates or debt‑service pressure could quickly compress the multiple. Investors should balance the rising sentiment score of 77 against the structural risks highlighted by recent policy shifts and debt dynamics. Alpha will arise from spotting when the market overreacts to short‑term reimbursement swings and underestimates the long‑term ambulatory growth.
Risk Factors
HCA Healthcare’s risk landscape is dominated by company‑specific operational and regulatory factors that could erode margins and earnings momentum. Debt servicing costs, reimbursement policy shifts, and patient mix dynamics are the primary levers that could compress profitability. While macro drivers such as overall health‑care spending growth remain supportive, the near‑term outlook hinges on how quickly the company can navigate these internal headwinds.
- Recent Decline Overhang
The 1‑year decline of 15.8% in HCA’s share price has been driven largely by margin compression following a $400 million pre‑tax hit from a policy change. If operating margins fall below 12% in the next quarter, the stock could see a further 8‑10% drop, assuming market sentiment remains unchanged. Key indicators are the quarterly earnings guidance, the trend in operating margin percentage, and any updates on the policy impact. The risk is most acute in the next 3‑6 months as the company reports the impact of the policy change on its financial statements. Investors should monitor the earnings call for any revisions to margin expectations and the narrative around the policy’s long‑term effects.
Frequently Asked Questions About HCA
Is HCA Healthcare (HCA) stock a good investment in 2026?
The bull case for HCA Healthcare centers on its dominant footprint in U.S. inpatient and outpatient care, which has driven consistent earnings beats in recent quarters. In Q1 2026, EPS rose to $7.15 versus the consensus $7.13, while revenue reached $19.109 B, slightly below the $19.072 B estimate but still above the prior quarter. The company’s 13.08 price‑to‑earnings ratio is well below the peer average of 53, suggesting a relative valuation discount. Risks include rising Medicaid policy costs, a $400 M pre‑tax hit from a recent policy change, and the uncertainty surrounding the HIX program. Despite these headwinds, HCA’s debt‑to‑EBITDA ratio remains manageable, and its free‑cash‑flow margin of roughly 18% offers a cushion for future capital returns.
What drives HCA Healthcare (HCA) stock price?
Primary price drivers for HCA stem from its earnings momentum and the perceived resilience of its hospital network. Quarterly EPS beats, such as the $0.28 increase in Q4 2025, reinforce confidence in operating performance. The company’s ability to maintain high occupancy rates in a competitive market also supports revenue growth, with Q4 2025 revenue of $19.513 B up 6.8% YoY. Investor sentiment has trended upward, reflected in a 77 sentiment score and a 11‑point delta over the past 14 days. Additionally, analyst upgrades, like UBS’s recent $579 target, help lift the stock relative to its 52‑week high of $556.52.
Does HCA Healthcare (HCA) pay a dividend?
HCA Healthcare does not currently distribute a dividend. Instead, the company prefers to reinvest earnings into expanding its network of ambulatory surgery centers and urgent‑care facilities. This strategy aims to capture higher margin services and diversify revenue streams. The reinvestment approach has been highlighted in recent earnings calls, where management emphasized capital allocation toward growth projects. Consequently, shareholders receive value through share price appreciation rather than periodic cash payouts.
How is HCA Healthcare (HCA) valued relative to peers?
Valuation metrics indicate that HCA trades at a 13.08 price‑to‑earnings ratio, well below the peer average of 53. This discount reflects the market’s underappreciation of HCA’s robust earnings consistency. The 52‑week low of $353.99 positions the stock 28.6% above its trough, while the current price of $413.36 sits 18.2% below the 52‑week high of $556.52. When compared to competitors such as Abbott Laboratories and Align Technology, HCA’s lower multiple suggests potential upside if the company continues to beat estimates. Analysts have maintained a mean price target of $453.38, indicating a modest 10% upside from the current level.
What are the risks of buying HCA Healthcare (HCA)?
Key risks include the impact of Medicaid policy changes, which can erode reimbursement rates and increase uninsured volumes. The company’s $400 M pre‑tax hit from a recent policy shift underscores this vulnerability. Rising operating costs, especially in labor and supplies, could compress margins if not offset by revenue growth. Additionally, the HIX program’s uncertain trajectory may introduce regulatory uncertainty. Finally, HCA’s debt load, while currently manageable, could strain cash flows if interest rates rise or if the company’s earnings momentum falters.
How does HCA Healthcare (HCA) compare competitively to other hospital operators?
HCA remains one of the largest U.S. hospital operators, with a network that spans 165 hospitals and 1,100 outpatient sites. Its breadth gives it negotiating leverage with payors and suppliers, translating into stable revenue streams. Compared to peers like AbbVie or Abbott Laboratories, HCA’s focus on acute care positions it in a sector that is less sensitive to cyclical drug pricing pressures. However, the company faces competition from integrated health systems such as UnitedHealth Group’s Optum, which offer bundled care models. HCA’s ability to maintain high occupancy rates and expand ambulatory services gives it a competitive edge in capturing high‑margin care.
What are the latest earnings results for HCA Healthcare (HCA) and how did they compare to estimates?
In Q1 2026, HCA reported EPS of $7.15, narrowly beating the $7.13 estimate, while revenue hit $19.109 B versus the $19.073 B consensus. The Q4 2025 earnings saw EPS climb to $8.01 from $7.53, a 6.8% increase, but revenue dipped to $19.513 B from $19.863 B, missing the $19.863 B estimate. Throughout 2025, HCA consistently beat EPS estimates, with the lowest beat of $0.23 in Q1 2025. The mixed revenue momentum in Q4 2025 highlights a potential slowdown, yet the company’s earnings resilience remains a positive signal.
What is the trend in HCA Healthcare (HCA) revenue over the last few quarters?
Revenue has shown a gradual flattening trend: Q1 2026 revenue stood at $19.109 B, slightly down from $19.513 B in Q4 2025 and $19.161 B in Q3 2025. The YoY growth rate slowed from 6.8% in Q4 2025 to a modest 1.5% in Q1 2026. Earlier quarters in 2025 displayed stronger momentum, with Q1 revenue at $18.321 B and Q2 at $18.605 B. This deceleration may reflect increased competition and regulatory headwinds, but the company still reports revenues above analyst expectations.
How has HCA Healthcare (HCA) stock performed over the past year?
Over the past twelve months, HCA’s stock has declined by 15.8%, falling from $480.00 at the start of the year to its current $413.36. The one‑month return was modest at 1.1%, but the three‑month period saw a 4.5% decline, and the six‑month performance dropped 22.4%. The recent dip aligns with broader healthcare sector volatility and concerns over Medicaid reimbursement changes. Despite the downturn, the stock remains 18.2% below its 52‑week high, indicating room for potential recovery if earnings momentum persists.
What is the consensus analyst price target for HCA Healthcare (HCA) and how many analysts hold buy/hold/sell?
Analysts currently set a mean price target of $453.38 for HCA, with a high of $579 and a low of $380. The rating distribution shows 17 buy, 12 hold, and only 1 sell recommendation. This split reflects a majority bullish stance, tempered by a single sell view that cites potential regulatory and cost‑pressure risks. The consensus target represents roughly a 10% upside from the current price of $413.36.
Has HCA Healthcare (HCA) announced any recent executive appointments that could affect performance?
On August 6 2026, HCA announced Dr. Michael Schlosser as Executive Vice President and Chief Clinical Officer, alongside Charles Gressle as President of the New Ambulatory Operations Group. These appointments signal a strategic emphasis on clinical excellence and expansion of ambulatory services, potentially boosting revenue mix. Management highlighted Dr. Schlosser’s track record in operational efficiency, which could translate into cost savings across the network. The leadership changes are expected to reinforce HCA’s focus on high‑margin outpatient care.
What impact does the HIX program have on HCA Healthcare (HCA) earnings?
The HIX program, a policy change affecting Medicaid reimbursements, introduced a $400 M pre‑tax hit that has pressured margins. Analysts have adjusted price targets downward in response to the uncertainty surrounding HIX’s long‑term viability. While the program’s immediate effect was a revenue miss in Q4 2025, HCA’s ability to maintain EPS beats suggests some resilience. Continued monitoring of HIX developments will be crucial for assessing future profitability.
Learn More
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
How Covered Calls Work and How to Use Them to Generate Income A practical breakdown of how covered calls work, how premium is priced, when to roll or let a call expire, and how they pair with a DailyIQ alert-driven approach.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
Bar Chart Patterns: Complete Guide to Structure, Breakouts, Retests, and Reliability Master bar chart patterns from boundary definition to breakout confirmation. Learn frequency vs reliability across timeframes, pullbacks/throwbacks, measured moves, and the behavioral traps that create false pattern signals.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
How to Use DailyIQ Email Alerts to Time Your Buys and Sells A practical walkthrough of what's inside a DailyIQ email alert and how to use the target price and upside percentage to time entries, exits, and rotations.
